BMC Genomics

RESEARCH

Open Access

IFNγ shapes macrophage inflammatory responses by STAT1 isoform-specific epigenetic and transcriptional mechanisms

Mojoyinola Joanna Akagha[1], Grigorios Georgolopoulos[2], David Martin[1], Katrin Meissl[1], Lena Amenitsch[1], Claus Vogl[1], Matthias Farlik[3], Nikolaus Fortelny[4], Florian Halbritter[5], Mathias Müller[1], Thomas Decker[6] and Birgit Strobl[1*]

Abstract

Background Interferon-γ (IFNγ) is a key cytokine that activates macrophages and is essential for the defence against intracellular pathogens. Beyond its immediate effects, IFNγ also shapes macrophages for subsequent encounters with pathogen-associated molecules by multiple mechanisms, including chromatin remodelling. Here, we employed integrated epigenomic and transcriptomic approaches utilizing primary macrophages from gene-modified mice to explore the role of STAT1 and its naturally occurring isoforms in these processes.

Results Using ChIP-seq for histone modifications (H3K27ac and H3K4me1) and RNA-seq, we demonstrate that STAT1 isoforms differentially modulate macrophage responses to lipopolysaccharide (LPS) following IFNγ conditioning. We provide genetic evidence that STAT1 isoforms exhibit distinct capacities to mediated IFNγ-induced changes in H3K27 acetylation at promoter and enhancer regions, thereby shaping transcriptional responses to LPS. We show that the STAT1β isoform, which lacks the C-terminal transactivation domain (TAD), is unable to mediate the repressive effect of IFNγ on transcriptional regulation by LPS but retains significant collaborative activity. Furthermore, we show that IFNγ attenuates the induction of a subset of antiviral genes and represses LPS-induced negative feedback loops, thereby amplifying the inflammatory response to pathogens. These effects are dependent on the presence of the STAT1 C-terminal TAD, highlighting its importance in fine-tuning the balance between inflammatory and antiviral responses.

Conclusions Our findings uncover isoform-specific roles of STAT1 in IFNγ-driven epigenetic regulation and macrophage conditioning, providing new insights into the control of inflammation and innate immunity.

Keywords Interferon- γ, Lipopolysaccharide (LPS), Macrophage conditioning, H3K27ac, H3K4me1, RNA-seq

*Correspondence:
Birgit Strobl
birgit.strobl@vetmeduni.ac.at
[1]Department of Biological Sciences and Pathobiology, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna 1210, Austria
[2]Genevia Technologies, Hämeenkatu 14 C 33, Tampere 33100, Finland
[3]Department of Dermatology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna 1090, Austria
[4]Department of Biosciences and Medical Biology, Center for Tumor Biology and Immunology, University Salzburg, Hellbrunner Straße 34, Salzburg 5020, Austria
[5]St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna 1090, Austria
[6]Max Perutz Labs (MPL), University of Vienna, Dr.-Bohr-Gasse 9, Vienna 1030, Austria

Background

Macrophages are innate immune cells that are crucial for the first line of defence against pathogens and tumour cells. Macrophages are also involved in the pathogenesis of inflammatory diseases, such as rheumatoid arthritis and arteriosclerosis, and neurodegenerative diseases [1].

Interferon-γ (IFNγ) is a potent macrophage-activating cytokine. It is pivotal for the immune defence against intracellular pathogens [2] by inducing transcriptional programs that orchestrate many cellular processes, including antigen-presentation and antimicrobial activity. IFNγ signals through the receptor-associated kinases JAK1 and JAK2, which in turn tyrosine-phosphorylate signal transducer and activator of transcription 1 (STAT1). Activated STAT1 homodimers translocate to the nucleus and bind to consensus motifs termed IFNγ-activated sequence (GAS) elements to induce target genes [3, 4]. STAT1 also induces the expression of other transcription factors, such as IFN-regulatory factors 1 and 8 (IRF1, IRF8), which bind to distinct consensus sequences and cooperate with STAT1 in the induction of IFN-stimulated genes (ISGs). IRF1 binds to IFN-stimulated response elements (ISRE) in target gene promoters and is central for the second wave of transcriptional responses to IFNγ [5]. Although STAT1 homodimers and IRF1 are the paradigmatic transcription factors in the IFNγ signalling cascade, ISRE-driven genes can also be induced through the activation of STAT1-STAT2 heterodimers which, together with IFN-regulatory factor 9 (IRF9), form the IFN-stimulated gene complex 3 (ISGF3). ISGF3 complexes containing unphosphorylated STAT2 ($ISGF3^{U}$) have been shown to regulate ISRE-driven genes during delayed responses to IFNγ [6]. Moreover, STAT1-IRF9 complexes were shown to induce the ISRE-driven genes *Cxcl10* and *Ifit2* [7–9].

Transcription factors use a DNA-binding domain to localize and bind to their cognate sequence elements at target gene regulatory elements and a transactivation domain (TAD) to interact with the general transcriptional machinery and recruit essential transcriptional co-factors, such as histone modifying and chromatin remodelling enzymes [10]. The TAD of STAT1 is localized at its C-terminus and is missing in the naturally occurring isoform STAT1β [11–13]. In vitro studies have demonstrated that STAT1β homodimers still bind to GAS elements in promoters of target genes in response to IFNγ but fail to recruit the histone acetyltransferase CBP/p300 and induce GAS-driven gene expression [11–14]. There is also evidence that STAT1 interacts weakly with CBP/p300 through its N-terminus, although it remains unclear whether this interaction occurs in the context of native chromatin [15]. In contrast, STAT1 isoforms appeared to be functionally redundant within an ISGF3 complex, implying that the TAD is provided by STAT2 [11, 16, 17]. Beyond its interaction with CBP/p300, the C-terminal TAD of STAT1 has also been reported to directly interact with minichromosome maintenance protein 5 (MCM5) and the DNA repair-associated tumour suppressor BRCA1 [18–20].

Complete STAT1 deficiency in humans and mice results in severe immunodeficiencies, characterized by life-threatening viral and bacterial infections [21–24]. Our studies using gene-modified mice that express either the full-length STAT1α ($Stat1^{\alpha/\alpha}$) or the truncated STAT1β isoform ($Stat1^{\beta/\beta}$) from the endogenous gene locus have demonstrated that STAT1β is capable of mediating IFNγ-dependent innate immune responses in vivo, albeit with significantly less potency than STAT1α [25]. While transcriptional responses to IFNγ were impaired but not entirely abolished in bone marrow-derived macrophages from $Stat1^{\beta/\beta}$ mice, studies on selected IFNγ target genes revealed gene-specific roles of STAT1β in histone acetylation at STAT1 target gene loci and the recruitment of RNA polymerase II [26]. However, genome-wide analyses of these effects are missing.

There is strong evidence that IFNγ-induced histone acetylation not only occurs at target genes but also at genes that are not transcriptionally regulated, the latter critically impacting on subsequent responses to inflammatory stimuli across both short-term priming and long-lasting innate immune memory (trained immunity) [27–30]. For example, IFNγ priming strongly augments LPS-induced expression of cytokine genes, including *Tnf* and *Il12p40*, by increasing the acetylation of histone 3 lysine 27 (H3K27ac) at distal regulatory elements in human monocytes and murine macrophages [31]. This process involves sustained occupancy of enhancer elements by STAT1 and IRF1 and increased recruitment of LPS-activated NFκB, transcriptional coactivators and DNA-dependent RNA polymerase II [31].

In this study, we sought to gain a deeper understanding of the mechanisms by which IFNγ priming modifies chromatin and how these modifications affect secondary responses to toll-like receptor (TLR) ligands. To achieve this, we conducted a comprehensive epigenomic and transcriptomic analysis to characterize changes of H3K27 acetylation and H3K4 monomethylation (H3K4me1) following IFNγ stimulation, as well as the subsequent transcriptional responses to the toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS). These analyses were performed in bone marrow-derived macrophages from wild-type (*WT*), $Stat1^{\alpha/\alpha}$, $Stat1^{\beta/\beta}$ and *Stat1* knockout ($Stat1^{-/-}$) mice. We show that cells only expressing STAT1β exhibit an impaired, yet not completely abolished, ability to induce H3K27 acetylation changes in response to IFNγ. This is accompanied by a significant defect in both the repression of enhancer activation and the transcriptional upregulation of a subset

of LPS-induced genes. Furthermore, we demonstrate that IFNγ pretreatment amplifies the induction of an ISGs subset by LPS, while simultaneously attenuating the expression of a subset of antiviral ISGs. These findings provide new insights into how IFNγ modulates the H3K27 acetylation landscape, regulates enhancer activity, and reshapes TLR4-mediated response.

Results

IFNγ-activated STAT1 isoforms differentially modulate LPS-induced cytokine induction

To test if the absence of STAT1 or its C-terminal TAD affects secondary responses to LPS, we utilized primary macrophages from four types of mice: STAT1-deficient (*Stat1*$^{-/-}$) mice, mice expressing only the full-length STAT1α isoform (*Stat1*$^{\alpha/\alpha}$), mice expressing only the truncated STAT1β isoform (*Stat1*$^{\beta/\beta}$), which lacks the C-terminal TAD [25], and wild-type (*WT*) mice. We pretreated macrophages with IFNγ for 14 h, followed by treatment with LPS for 1, 3 and6 h, and then analyzed cytokine mRNA expression (Fig. 1a). IFNγ pretreatment strongly increased LPS-induced expression of *Il12p40* and *Tnf* in *WT* but not in *Stat1*$^{-/-}$ cells (Fig. 1b and c). *Stat1*$^{\alpha/\alpha}$ cells showed a similar cytokine gene expression pattern as *WT* cells, whereas *Stat1*$^{\beta/\beta}$ cells showed a reduced, yet not completely abolished, augmentation of LPS-induced *Il12p40* and *Tnf* expression by IFNγ (Fig. 1b and c and Additional file 1: Fig. S1a and S1b for the statistical analysis of IFNγ pretreated versus non-pretreated cells).



Fig. 1 IFNγ-activated STAT1 isoforms differentially modulate LPS-induced cytokine induction. **a** Experimental workflow: Bone marrow-derived macrophages (BMDM) from wild-type (*WT*), *Stat1*$^{\alpha/\alpha}$, *Stat1*$^{\beta/\beta}$ and *Stat1*$^{-/-}$ mice were stimulated with IFNγ for 14 h, washed with PBS and treated with LPS for the times indicated. **b-d** Expression of *Il12p40* (b), *Tnf* (c) and *Il10* (d) mRNA was determined by RT-qPCR. Expression levels were normalized to the housekeeping gene *Ube2d2*. Mean values ± SD from 3 independent experiments are given. Statistical analysis was done with log-transformed data; 2-way ANOVA with repeated measurement and Tukey HSD posthoc test; significances are only indicated for the comparisons between IFNγ pretreated and non-pretreated cells (LPS versus IFNγ, LPS); * $p \le 0.05$, ** $p \le 0.01$, *** $p \le 0.001$

In contrast to the increase of inflammatory cytokine induction, IFNγ represses a subset of LPS-induced genes, including *Il10* [32]. In line, we found reduced upregulation of *Il10* by LPS in IFNγ pretreated *WT* cells as compared to cells that were only treated with LPS (Fig. 1d, and Additional file 1: Fig. S1c). $Stat1^{\alpha/\alpha}$ cells showed a stronger repression of *Il10* induction by LPS compared to *WT* cells at early time points after treatment, whereas IFNγ pretreatment barely affected the induction of *Il10* in $Stat1^{\beta/\beta}$ cells (Fig. 1d and Additional file 1: Fig. S1c). Notably, early induction of *I110* by LPS alone was higher in $Stat1^{\beta/\beta}$ and $Stat1^{-/-}$ than in $Stat1^{\alpha/\alpha}$ and *WT* cells (Fig. 1d), arguing for a suppressive effect of the STAT1 C-terminal TAD on the early induction of IL-10.

Collectively, these data provide proof-of-concept that IFNγ-activated STAT1 isoforms differ in their ability to modulate the transcriptional responses to LPS.

STAT1 isoforms differentially regulate H3K27 acetylation and deacetylation in response to IFNγ

To analyse how STAT1 and its isoforms regulate histone modifications in response to IFNγ at the genome-wide level and how they impact on transcriptional responses to LPS, we treated *WT*, $Stat1^{\alpha/\alpha}$, $Stat1^{\beta/\beta}$ and $Stat1^{-/-}$ macrophages with IFNγ for 14 h followed by 3 h or6 h LPS treatment and performed (i) ChIP-seq for H3K27ac and H3K4me1 and (ii) RNA-seq experiments (Fig. 2a).

First, we analysed genome-wide effects on H3K27 acetylation, a histone mark for active promoters and enhancers [33]. H3K27ac signals across the genome showed a high correlation between replicates and clustering according to the treatments (Additional file 1: Fig. S2a), indicating low variation between biological replicates and good data quality. To quantify the overlap of H3K27ac signals between cells of the different genotypes across treatments, we computed the Jaccard similarity index [34] between samples based on the pairwise overlap of peaks called for each sample. The relative similarity between untreated and IFNγ-treated cells was stronger than between untreated and LPS-treated cells, indicating that LPS has a more pronounced impact on H3K27ac than IFNγ-pretreatment (Additional file 1: Fig. S2b). To derive a unified peak set that represents recurrent H3K27ac peaks called across all samples, we developed a custom approach that collapses overlapping peaks into a consensus peak set (Additional file 1: Fig. S2c and methods). The majority of the H3K27ac peaks were identified in intronic regions, followed by intergenic regions and promoter-transcriptional start sites (TSS) (Fig. 2b). As a quality control, we performed *de novo* transcription factor motif discovery in the sequences of our H3K27ac consensus peak set and found the highest enrichment for motifs resembling the SPI-B and AP-1 binding motifs (Fig. 2c). SPI-B shares its core consensus motif with PU.1 (also named SPI-1) [35, 36], a pioneering transcription factor in macrophages that sets the stage for macrophage-specific transcriptional response to LPS [37]. AP-1 family members are known to contribute to the response to many TLR ligands, including LPS [38].

To better understand the role of STAT1 and its C-terminal TAD in the regulation of H3K27 acetylation in response to IFNγ, we focussed on untreated and IFNγ-treated *WT*, $Stat1^{\alpha/\alpha}$, $Stat1^{\beta/\beta}$ and $Stat1^{-/-}$ cells. We performed unsupervised clustering (*K*-means, $k=4$) on H3K27ac consensus peaks that changed by the IFNγ treatment (pairwise Wald test, adjusted $p \le 0.001$) (Fig. 2d). Peaks in clusters 2 and 3 showed an increase, whereas peaks in clusters 1 and 4 showed a decrease in H3K27 acetylation response to IFNγ (Fig. 2d). Surprisingly, we observed more pervasive changes in H3K27ac in $Stat1^{\alpha/\alpha}$ than in *WT* cells at the peaks that displayed significant changes across treatments and genotypes, with a stronger effect on the deacetylation of H3K27 than on its acetylation. In contrast, $Stat1^{\beta/\beta}$ cells had weaker changes in H3K27ac than *WT* cells at this subset of peaks (Fig. 2d). $Stat1^{-/-}$ cells clustered together with untreated *WT*, $Stat1^{\alpha/\alpha}$ and $Stat1^{\beta/\beta}$ cells, indicating that most changes in H3K27ac are mediated by STAT1. We observed a 1.6-fold enrichment of intergenic regions in cluster 1 and a 2.2-fold enrichment of promoter-TSS regions in cluster 4 peaks (Binomial test, $p \le 0.001$) (Additional file 1: Fig. S2d).

Peaks that showed an IFNγ-induced increase in H3K27 acetylation (cluster 2 and cluster 3) were found to harbour ISRE and IRF1 binding motifs (Fig. 2d and Additional file 1: Fig. S3a). This is in line with previous reports showing that at later stages of the IFNγ response, the STAT1 binding profile changes from GAS to IRF1 and ISRE elements, which are highly similar and can be occupied by STAT1 as part of ISGF3 complexes or by IRF1 [31, 39, 40]. Cluster 2 and cluster 3 peaks also showed an enrichment in binding sites for the IFNγ-inducible transcription factors IRF2 and IRF8 against genomic background (Additional file 1: Fig. S3a) and include peaks annotated to well-known STAT1 target genes, such as *Irf1* and *Ciita* (Additional file 2: Table S1).

H3K27ac peaks that were downregulated in response to IFNγ (cluster 1 and cluster 4) were found to harbour consensus motifs for members of the activator protein 1 (AP-1) family, such as FRA1, FRA2, FOS and JUNB (Fig. 2d and Additional file 1: Fig. S3a). Comparison between the clusters revealed a stronger enrichment of the IRF1 motif in cluster 3 than in cluster 2 and a stronger enrichment of the AP-1 motif in cluster 4 than in cluster 1 (Additional file 1: Fig. S3b).

Differential H3K27ac analysis identified 2576 peaks gaining and 2315 peaks loosing H3K27 acetylation in response to IFNγ in *WT* cells (DESeq2, padj-value ≤ 0.05

Figure 2



Fig. 2 STAT1 isoforms mediate overlapping but also unique changes in H3K27ac

and log2 fold-change ≥ 1; Fig. 2e). *Stat1*$^{\alpha/\alpha}$ cells showed a comparable number of acetylated peaks but a higher number of deacetylated peaks compared to *WT* cells, whereas *Stat1*$^{\beta/\beta}$ cells had lower numbers of both acetylated and deacetylated peaks than *WT* cells (Fig. 2e). In *Stat1*$^{-/-}$ cells, we observed considerably fewer differentially acetylated H3K27ac peaks than in cells of all other genotypes (Fig. 2e). Peaks that gained H3K27ac in response to IFNγ were preferentially found at promoter-TSS, intronic and intergenic regions, whereas no significant enrichment for genomic features were found for deacetylated peaks in *WT* cells (Additional file 1: Fig. S3c). The genomic location of H3K27ac peaks were mostly concordant between cells of the different genotypes, except for a gain in exonic regions in *Stat1*$^{\alpha/\alpha}$ cells and a muted effect in *Stat1*$^{\beta/\beta}$ and *Stat1*$^{-/-}$ cells, particularly for promoter-TSS and intronic regions, respectively (Additional file 1: Fig. S3c).

In line with our published data on H3 N-terminal pan-acetylation [26], we found reduced, but not completely abolished, H3K27ac at the *Irf1* promoter and a nearly complete impairment in the upregulation of H3K27ac at the *Ciita* promoter in *Stat1*$^{\beta/\beta}$ cells (Additional file 1: Fig. S3d and S3e). *Stat1*$^{\alpha/\alpha}$ cells showed a comparable increase in H3K27ac at the *Irf1* and *Ciita* promoters as observed in *WT* cells (Additional file 1: Fig. S3d and S3e).

Focusing on the differences between *WT*, *Stat1*$^{\alpha/\alpha}$ and *Stat1*$^{\beta/\beta}$ cells, we found a strong overlap in regulated peaks, as well as peaks that were exclusively regulated in cells of the different genotypes (Fig. 2f). The difference between *WT*, *Stat1*$^{\alpha/\alpha}$ and *Stat1*$^{\beta/\beta}$ cells was higher for deacetylated than acetylated H3K27 peaks. Peaks that were exclusively upregulated in *Stat1*$^{\alpha/\alpha}$ cells showed an enrichment in DNA motifs bound by methyl-CpG-binding proteins, such as MBD2 and MECP2, and by histone H4 transcription factor (HINFP1/1), an interactor of MBD2 also known as MIZF [41, 42], compared to the acetylated peaks in the other genotypes (Fig. 2g). This suggest that STAT1α alone specifically increases H3K27ac at CpG-rich promoters. In contrast, these motifs were enriched in deacetylated H3K27 peaks in *WT* and, to a lesser extent, *Stat1*$^{\beta/\beta}$ cells, indicating opposing regulation of H3K27ac at CpG-rich promoters compared with *Stat1*$^{\alpha/\alpha}$ cells.

Collectively, these data indicate that IFNγ-induced H3K27 acetylation is associated with an enrichment in ISRE/IRF consensus motifs, whereas H3K27 deacetylation is associated with the presence of AP-1 family motifs. Moreover, the data underscores the crucial role of the STAT1 C-terminal TAD in IFNγ-induced H3K27 acetylation and uncover a previously unrecognized role in H3K27 deacetylation.

STAT1 isoforms differentially regulate enhancer activity in response to IFNγ

Enhancers are marked by monomethylated K4 on histone H3 (H3K4me1) [43, 44] and can be roughly classified into active and inactive (poised) enhancers based on the presence or absence of H3K27 acetylation, respectively [45].

H3K4me1 signals showed a high correlation between genotypes and treatments (Additional file 1: Fig. S4a) and a lower dynamic range than H3K27ac signals, both across the genome (Additional file 1: Fig. S4b) and at the top 5000 most dynamically regulated regions (Additional file 1: Fig. S4c) in cells of all genotypes.

We next focussed on changes in H3K4me1 at H3K27ac consensus peaks. At the genome-wide level, *Stat1*$^{\alpha/\alpha}$ cells showed a modestly higher increase in H3K4me1 in response to IFNγ than *WT* cells, whereas *Stat1*$^{-/-}$ cells and, to a lesser extent, *Stat1*$^{\beta/\beta}$ cells showed an increased loss of H3K4me1 at H3K27ac peaks (Fig. 3a).

We then classified enhancers into (i) activated enhancers (high H3K4me1 and acquisition of H3K27ac in response to IFNγ) and (ii) inactivated enhancers (high H3K4me1 and H3K27ac in untreated cells and loss of H3K27ac in response to IFNγ). We found 2282 activated and 2473 inactivated enhancers (Fig. 3b) in *WT* cells. IFNγ inactivated more enhancers in *Stat1*$^{\alpha/\alpha}$ than in *WT* cells (3111 and 2473, respectively), whereas the number of activated enhancers was comparable (2247 and 2282, respectively; Fig. 3b). *Stat1*$^{\beta/\beta}$ cells had less activated and inactivated enhancers than *WT* cells but more than *Stat1*$^{-/-}$ cells, indicating that STAT1β can mediate the activation and inactivation of a subset of STAT1-regulated enhancer elements (Fig. 3b).

Although the enhancer landscape in macrophages is predetermined by the pioneering transcription factor PU.1, there is also evidence that certain genomic regions lacking H3K4me1, termed latent enhancers, can acquire H3K4me1 and H3K27ac in response to LPS or IFNγ [32, 39]. However, compared to the activating effect on poised enhancers, the effect on latent enhancers was small in our experimental set-up (Additional file 1: Fig. S4d).

Similar to our findings for H3K27ac consensus peaks, activated and inactivated enhancers showed a large overlap but, surprisingly, also elements that were exclusively regulated in either *WT*, *Stat1*$^{\alpha/\alpha}$ or *Stat1*$^{\beta/\beta}$ cells (Fig. 3c). Enhancers that were exclusively activated in *Stat1*$^{\alpha/\alpha}$ cells had the strongest enrichment for the HD/18 transcription factor-binding motif archetype, which is utilized by members of the homeobox transcription factor family, such as HOXA10, HOXA13 and HOXB13, compared to the activated enhancer peaks in the other genotypes (Fig. 3d). Enhancers that were exclusively activated in *Stat1*$^{\beta/\beta}$ cells, had the strongest enrichment for the OVOL1 motif, whereas there was no strong motif enrichment in enhancers exclusively activated by IFNγ in



Fig. 3 STAT1 isoforms differ in their ability to activate and inactive enhancers in response to IFNγ. **a** Violin plots showing the log2 ratio over H3K27ac consensus peaks of H3K4me1 signal enrichment between IFNγ treated and untreated (UT) *WT*, *Stat1*$^{\alpha/\alpha}$, *Stat1*$^{\beta/\beta}$ and *Stat1*$^{-/-}$ cells. **b** Scatter plots of H3K4me1 *versus* H3K27ac in *WT*, *Stat1*$^{\alpha/\alpha}$, *Stat1*$^{\beta/\beta}$ and *Stat1*$^{-/-}$ BMDM for IFNγ-activated enhancers (left panel) and IFNγ-inactivated enhancers (right panel) in *WT*, *Stat1*$^{\alpha/\alpha}$, *Stat1*$^{\beta/\beta}$ and *Stat1*$^{-/-}$ BMDM. The numbers of activated and inactivated enhancers are indicated in the respective quadrant of the scatter plots for cells of the four genotypes. **c** Proportional Venn diagram of activated and inactivated enhances in *WT*, *Stat1*$^{\alpha/\alpha}$ and *Stat1*$^{\beta/\beta}$ cells. **d** Top 10 enriched transcription factor-binding motifs in enhancers that are exclusively activated or inactivated in *WT*, *Stat1*$^{\alpha/\alpha}$, *Stat1*$^{\beta/\beta}$ and *Stat1*$^{-/-}$ cells (archetype) ranked by Benjamini-Hochberg adjusted p-value with log2 fold ratio > 0.5

WT and *Stat1*$^{-/-}$ cells (Fig. 3d). For enhancers that were exclusively inactivated in cells from one of the four genotypes, we found the strongest enrichment for the NRF1 motif archetype in *WT* cells and ZNF384 in *Stat1*$^{\alpha/\alpha}$ cells (Fig. 3d). To our knowledge, none of these transcription factors has been directly implicated in the transcriptional responses to IFNγ. *Stat1*$^{-/-}$ cells showed an enrichment of the IRF1 consensus motif in the peaks that were exclusively deacetylated in these cells (Fig. 3d). This result may be attributed to the impaired expression of IRF1 in the absence of STAT1, suggesting that IRF1 is essential for sustaining H3K27 acetylation at specific genomic regions.

Taken together, these data show that STAT1 isoforms differentially regulate enhancer activity in response to IFNγ. The presence of only STAT1α mainly increases IFNγ-induced enhancer inactivation, whereas the presence of only STAT1β results in an impaired, yet not completely abolished, activation and inactivation of STAT1-regulated enhancer elements.

IFNγ treatment blocks the LPS-induced upregulation of a subset of antiviral genes

To investigate the effect of IFNγ pretreatment on LPS-induced transcriptional responses we performed RNA-seq analysis (see Fig. 2a for the experimental scheme). Differential gene expression analysis of all treatment conditions identified 6910 differentially expressed genes in *WT* cells (DESeq2, likelihood ratio test, adjusted $p \leq 0.01$). *K*-means clustering classified differentially expressed genes into 9 groups (Fig. 4a). In keeping with the focus of our study, we concentrated on clusters that showed either collaborative (additive or synergistic) gene regulation by IFNγ and LPS (cluster 1 and cluster 5) or a repression of LPS-induced up- or downregulation by IFNγ (cluster 2 and cluster 7, respectively) (Fig. 4a and b).

Gene ontology analysis (GO) showed enrichment of genes annotated to distinct biological functions in each of the clusters (Fig. 4c). Cluster 1, which contains genes that are additively or synergistically induced by IFNγ and LPS, as exemplified by *Ido1*, *Gbp6* and *Bcl9* (Fig. 4b), was strongly enriched in genes annotated for the response to IFNβ (Fig. 4c). In line, cluster 1 genes showed a strong enrichment in ISRE and IRF1 motifs in their promoter region (Additional file 1: Fig. S5). Surprisingly, ISRE and IRF1 motifs were also enriched in promoters of cluster 2 genes, the group of genes that showed a repression of LPS-induction by IFNγ (Additional file 1: Fig. S5). Closer examination of these genes revealed that cluster 2 contains well-known IFN-inducible antiviral genes, such as 2'–5'-oligoadenylate synthase 2 (*Oas2)* and IFN-induced protein with tetratricopeptide repeats 3B (*Ifit3b)* (Fig. 4b and Additional file 3: Table S2). These results identify two classes of LPS-regulated and ISRE- or IRF1-driven genes, which are either enhanced (cluster 1) or repressed (cluster 2) by pretreatment with IFNγ. The latter class was enriched in genes annotated for the response to virus and related categories (Fig. 4c), suggesting that IFNγ specifically represses the induction of a subset of antiviral genes in response to LPS.

Cluster 5, which contains genes that are basally expressed in macrophages and downregulated by IFNγ and LPS, as exemplified by *Tmem154*, *Cdk20* and *Uck2* (Fig. 4b), showed enrichment in genes annotated for DNA-dependent replication, mitotic sister chromatin segregation and other categories related to cell division (Fig. 4c). These data are consistent with reported anti-proliferative activities of IFNγ [46] and indicate collaboration with LPS in the downregulation of cell cycle genes. Cluster 5 also contains genes annotated for DNA metabolic processes, such DNA-methyltransferase 1 (*Dnmt1*) (Additional file 3: Table S2). Cluster 5 genes showed enrichment for binding motifs of E2F family members, such as E2F7 and E2F1 (Additional file 1: Fig. 5a), which have a well-established role in the regulation of cell cycle genes and the induction of apoptosis [47].

Cluster 7 genes, whose downregulation by LPS was blocked by IFNγ, showed the strongest enrichment for genes annotated for ribosome biogenesis, ribonucleoprotein complex biosynthesis and non-coding RNA (ncRNA) processing (Fig. 4c). Cluster 7 genes also contained the anti-apoptotic gene *Bcl2* and cyclin E1 encoding gene *Ccne1* (Fig. 4b). Transcription factor binding motif analysis showed the strongest enrichment for C-MYC and MNT (Max network transcriptional repressor) in cluster 7 genes (Additional file 1: Fig. S5).

Taken together these data show that IFNγ pretreatment blocks the LPS-induced upregulation of a subset of antiviral genes and the LPS-induced downregulation of genes mainly associated with mitochondrial RNA metabolism or ribosome biogenesis.

IFNγ-mediated inhibition of gene induction by LPS requires the presence of STAT1 and its C-terminal TAD

To test whether STAT1 modulates the effect of IFNγ pretreatment on LPS-induced gene expression changes over baseline (untreated) we fit a generalized linear model (glm) where we regressed log2 fold changes over untreated as a function of the 3-way interaction between IFNγ pretreatment, duration of LPS stimulation (3–6 h) and the genotype. For all clusters of genes tested, we found significant interaction both between genotype and IFNγ pretreatment (cluster 2 genes: Likelihood-ratio X2 = 45.98, DF = 3; p-value = 5.72e-10) as well as between genotype and LPS exposure time (cluster 2 genes: Likelihood-ratio X2 = 51.73, DF = 3; p-value = 3.42e-11) as tested by two-way ANOVA (Additional file 4: Table S3).

We then quantified the differences in the log2 fold change in gene expression of cells treated with either



Fig. 4 IFNγ pre-treatment affects LPS-responses in ***WT*** BMDM. **a** Heatmap of 6910 differentially expressed genes (K-means clustering, k = 9) with an adjusted p-value ≤ 0.01. **b** RNA-seq data (TPM) of example genes from cluster 1, cluster 2, cluster 5 and cluster 7. **c** Top 10 enriched gene ontology (GO) pathways (biological processes) in cluster 1, cluster 2, cluster 5 and cluster 7



Fig. 5 IFNγ pre-treatment differentially affects LPS-responses in *WT*, *Stat1α/α*, *Stat1β/β*and *Stat1*$^{-/-}$ BMDM. **a** Box plots showing log2 fold changes in gene expression of the different treatments over untreated *WT*, *Stat1*$^{α/α}$, *Stat1*$^{β/β}$ and *Stat1*$^{-/-}$ cells in cluster 1 (top) and cluster 2 (bottom). For reasons of clarity, statistical significances are only indicated for the differences in the log2 fold change over untreated between LPS alone (L) and after pre-treatment with IFNγ (GL) across the genotypes. Stars denote Tukey HSD adjusted p-values. See Additional file 5: Table S4 for the Tukey HSD results of all comparisons. * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$. **b**, **c** Heatmaps showing the expression patterns of examples genes from cluster 1 (b) and cluster 2 (c). TPM values have been scaled for each gene so that expression values ranging from 100 (max TPM for this gene) to 0 were obtained

LPS alone (L) or with IFNγ prior to LPS treatment (GL) over untreated cells in each cluster. IFNγ pretreatment enhanced mean LPS-induced gene expression of cluster 1 genes in *WT*, *Stat1*$^{\alpha/\alpha}$ and *Stat1*$^{\beta/\beta}$ cells but not in *Stat1*$^{-/-}$ cells (Fig. 5a, upper panel and Additional file 5: Table S4 for Tukey HSD results). At the single gene level, this expression pattern was found for many well-known ISGs, such as *Oas3* and *Zbp1* (Fig. 5b). However, there were a few notable exceptions, such as *Ido1* and *Tgtp1*, which were synergistically induced by IFNγ and LPS in *WT* and *Stat1*$^{\alpha/\alpha}$ cells but not in *Stat1*$^{\beta/\beta}$ cells (Fig. 5b). *Ido1* and *Tgtp1* showed an even stronger enhancement in *Stat1*$^{\alpha/\alpha}$ than in *WT* cells, suggesting that STAT1β is not only incapable of inducing these genes but also limits their induction by STAT1α.

For cluster 2 genes, we found a repressive effect of IFNγ on LPS-induced upregulation in *WT* and *Stat1*$^{\alpha/\alpha}$ cells, whereas this was strongly diminished in *Stat1*$^{\beta/\beta}$ and *Stat1*$^{-/-}$ cells (Fig. 5a, lower panel and Additional file 5: Table S4 for Tukey HSD results). Cluster 2 genes contained well-known IFN-stimulated genes (ISG) with antiviral activity, such as *Mx1*, and genes that were induced by LPS in a STAT1-independent manner, such as *Irak3*, *Lcn2* and *Anxa7* (Fig. 5c). IRAK3 (also named IRAK-M) and LCN2 are both essential negative regulators of macrophage activity [48, 49].

LPS-induced repression of cluster 5 genes was enhanced by IFNγ in *WT*, *Stat1*$^{\alpha/\alpha}$, *Stat1*$^{\beta/\beta}$ and, to a lesser extent, *Stat1*$^{-/-}$ cells, whereas LPS-induced repression of cluster 7 genes was inhibited by IFNγ in *WT* and *Stat1*$^{\alpha/\alpha}$ but not *Stat1*$^{\beta/\beta}$ and *Stat1*$^{-/-}$ cells (Additional file 1: Fig. S6).

Taken together, these data indicate that STAT1β mediates large parts of the collaborative effects of IFNγ on transcriptional responses to LPS (cluster 1) but fails to inhibit the up- and downregulation of subsets of LPS-responsive genes (cluster 2 and cluster 7). Furthermore, the data indicate that the collaborative inhibition of gene expression by IFNγ and LPS (cluster 5) is partially independent of STAT1.

Inhibition of LPS-induced enhancer activation by IFNγ requires the presence of the STAT1 C-terminal TAD

IFNγ affects LPS responses by multiple mechanisms, including induction of feedback inhibitors, upregulation of signalling components [2, 50–52] and H3K27 acetylation at enhancer elements [31, 32]. To test whether IFNγ-induced H3K27ac changes at enhancers (as defined in Fig. 3b) correlate with effects on transcriptional responses to LPS, we tested for differences in the frequency of activated and inactivated enhancers ± 100 kb around the TSS of genes in each of the *WT* clusters (cluster 1–9) with all treatment conditions compared to untreated cells.

Cluster 1 and cluster 2, which contain genes that are upregulated by LPS, showed an enrichment of activated enhancers in LPS-stimulated versus untreated cells (Fig. 6a). In cluster 1, the enrichment of activated enhancers was higher in IFNγ + LPS treated cells than in cells treated with LPS alone, indicating collaborative enhancer activation by the two treatments. For example, collaborative enhancer activation was observed around the *Cd274* gene, which encodes the checkpoint protein PD-L1 (Fig. 6b). Of note, 4 out of the 5 peaks at these two genes are located in regions that were identified as enhancers by multiple methods by the group of Ido Amit [53] (indicated with an E in Fig. 6c).

In line with a previous report [31], we also found collaborative enhancer activation at the IL-12p40-encoding gene *Il12b* (Additional file 1: Fig. S7a). In cluster 2, the enrichment of activated enhancers was lower in response to IFNγ + LPS than LPS alone, suggesting that IFNγ pretreatment inhibits enhancer activation in this group of genes (Fig. 6a). This pattern is exemplified at the *Irak3* and *Mefv* gene loci, the latter encoding PYRIN (Fig. 6c and Additional file 1: Fig. S7b). Similarly, we observed IFNγ-induced inhibition of enhancer activation at the *Il10* locus (Additional file 1: Fig. S7c).

For the genes in cluster 5, which are downregulated by IFNγ and LPS, we found an enrichment of inactivated enhancers in response to LPS (Fig. 6a). IFNγ pretreatment did not alter the frequency of inactivated enhancers in cluster 5 genes, arguing against a collaboration of IFNγ and LPS in enhancer inactivation of this group of genes. For the LPS-repressed genes in cluster 7, we found a weak enrichment of inactivated enhancers, in response to LPS but not IFNγ + LPS (Fig. 6a), suggesting that the downregulation of only a small subset of cluster 7 genes is associated with enhancer inactivation and that this is blocked by IFNγ pretreatment.

Collectively, these data show that both the enhancing and repressive effects of IFNγ on gene induction by LPS correspond with effects on LPS-induced enhancer activation (cluster 1 and cluster 2 genes), whereas effects on LPS-repressed genes (cluster 5 and cluster 7 genes) appear to be mostly unrelated to alterations in enhancer activity.

Having established that IFNγ pretreatment affects LPS-induced enhancer activation in cluster 1 and cluster 2 genes, we next quantitatively compared the overall gain of H3K27ac signal at the TSS ± 25 kbp in *WT*, *Stat1*$^{\alpha/\alpha}$, *Stat1*$^{\beta/\beta}$ and *Stat1*$^{-/-}$ cells across treatments. In line with the data shown in Fig. 6a, IFNγ-pretreatment increased LPS-induced H3K27ac in cluster 1 genes (Fig. 6d). As expected, cluster 1, which was strongly enriched in IFN response genes, barely showed any increase in H3K27ac in *Stat1*$^{-/-}$ cells across treatments. The IFNγ-dependent



Fig. 6 Association of enhancers changes with transcriptional clusters. **a** Enrichment of activated and inactivated enhancers under the different treatment condition in the distinct transcriptional clusters in *WT* cells: IFNγ-treated versus untreated cells (IFNγ), LPS-treated versus untreated cells (LPS) and IFNγ pretreated and 3 h LPS stimulated versus untreated cells (IFNγ + LPS). Color encodes for the log2 ratio over untreated and size encodes for the binomial test Benjamini-Hochberg adjusted p-value (-log10). **b**, **c** Normalized H3K27ac density tracks around the *Cd274* gene (b) and the Irak3 gene (c) in *WT* cells. The merged normalized H3K27ac signal from 3 independent experiments is shown. H3K27ac peaks of interest are indicated by a box and enhancers identified by Lara-Astiaso [53] are indicated by an E under the box. **d** Changes in H3K27 acetylation at the TSS ± 25 kb of cluster 1 and cluster 2 genes in *Stat1*$^{\alpha/\alpha}$, *Stat1*$^{\beta/\beta}$ and *Stat1*$^{-/-}$ cells compared to *WT* cells in response to IFNγ (G), IFNγ followed by LPS for 3 h (GL) or only LPS (L) for 3 h

increase in H3K27ac was similar between *WT* and *Stat1*$^{\alpha/\alpha}$ cells, whereas it was slightly lower in *Stat1*$^{\beta/\beta}$ cells (Fig. 6d, upper panel). However, IFNγ pretreatment caused a similar fold-change in H3K27ac in *Stat1*$^{\beta/\beta}$ as in *WT* and *Stat1*$^{\alpha/\alpha}$ cells, suggesting that collaborative enhancer activation is largely intact in *Stat1*$^{\beta/\beta}$ cells. In cluster 2 genes, IFNγ pretreatment reduced the overall gain in H2K27ac at distal elements in response to LPS in *WT* cells, further supporting our finding that IFNγ blocks LPS-induced enhancer activation at a subset of LPS-responsive genes (Fig. 6d, lower panel). In line with the well-established role of STAT1 in the cellular response to LPS, the gain in H3K27ac was reduced, but not absent, in *Stat1*$^{-/-}$ cells. IFNγ failed to block LPS-induced H3K27 acetylation in *Stat1*$^{-/-}$ and *Stat1*$^{\beta/\beta}$ cells and even slightly increased H3K27ac in response to LPS in *Stat1*$^{\beta/\beta}$ cells (Fig. 6d, lower panel). Impaired suppression of LPS-induced H3K27 acetylation in *Stat1*$^{-/-}$ cells



Fig. 7 Defining the regulatory networks that drive responses to LPS and IFNγ + LPS. **a** Top 5 variable transcription factors (TFs) in response to the treatments using data from *WT* and *Stat1*$^{-/-}$ cells. **b** Schematic representation of the regulatory network construction. **c** The top 150 most variable TFs (according to variance across RNA-seq data from *WT* and *Stat1*$^{-/-}$ cells) were used for TF network reconstruction using the elastic-GRN approach implemented in GRaNIE [54]. This method enables the identification of transcription factors, acetylated peaks (putative enhancers), and genes that exhibit significant co-variation within the dataset. These elements are organized into groups of target genes (communities) that are potentially regulated by one or more transcription factors, mediated by the presence of putative binding sites within the co-varying acetylation patterns of the peaks. **c** Regulatory network initiated by transcription factors (TF) in response to the treatments indicated. TFs in the nodes and select TFs in the distinct target gene communities are shown. For clarity, a maximum of 50 connections to target genes per community are shown. Left panel: GRaNIE was provided with expression data (RNA-seq raw counts) and H3K27ac peaks (location and counts) from untreated and LPS-treated (3 h and 6 h) *WT* and *Stat1*$^{-/-}$ cells. Right panel: GRaNIE was provided with expression data (RNA-seq raw counts) and H3K27ac peaks (location and counts) from untreated and IFNγ + LPS -treated (3 h and 6 h) *WT* and *Stat1*$^{-/-}$ cells

and, to a lesser extent in *Stat1*$^{\beta/\beta}$ cells, compared with *Stat1*$^{\alpha/\alpha}$ and *WT* cells is for example, observed at the *Irak3* gene (Fig. 6c and Additional file 1: Fig. S7d-f).

Taken together, these data show that the STAT1 C-terminal TAD is required for the repressive effects of IFNγ on LPS induced enhancer activation, whereas it is largely dispensable for collaborative enhancer activation by IFNγ and LPS.

IFNγ pretreatment reshapes the transcription factor network utilized by TLR4 signalling

IFNγ and LPS induce the expression of a wide range of transcription factors, such as IRF1, IRF8, ATF3 and JUNB (Fig. 7a), leading to transcription factor cascades that amplify the initial response and establish complex expression patterns required for proper responses to extracellular stimuli. To reconstruct the gene regulatory network (GRN) underlying the LPS and IFNγ + LPS responses, we provided GRaNIE [54] with gene expression data (RNA-seq raw counts) and H3K27ac peaks (location and raw counts) from untreated and LPS-treated (3 h and 6 h) or untreated and IFNγ + LPS-treated *WT* and *Stat1*$^{-/-}$ cells. The peak sequences were scanned for occurrences of binding motifs for the top 150 variable transcription factors and the program assigns transcription factors to

differentially acetylated peaks (DA) and DA peaks to target genes, thereby defining communities (Fig. 7b).

As expected, the ISGF3 components STAT1, STAT2 and IRF9 were identified as part of the core transcription factor network mediating responses to LPS, regardless of IFNγ pretreatment. IRF1, IRF7 and IRF8 also emerged as central regulators in both treatments, consistent with their strong upregulation by IFNγ and LPS (Additional file 1: Fig. S8). Notably, the target gene communities of STAT1, STAT2, IRF1 and IRF9 differed between treatments, indicating treatment-specific interactions with other transcriptional regulators (Additional file 1: Fig. S9a). However, it is important to consider that the binding motifs annotated for these STAT and IRF family members are highly similar (Additional file 1: Fig. S9b).

Our analysis identified MAZ (Myc-associated zinc finger protein), ETV5 (ETS variant transcription factor 5), NFYB (nuclear transcription factor Y subunit beta), E2F8 (E2F transcription factor 8) and ATF4 (activating transcription factor 4) as key transcription factors driving the epigenetic (H3K27ac) and transcriptional response to IFNγ + LPS (Fig. 7c, right panel). Furthermore, our analysis revealed that KLF8 (KLF transcription factor 8), NRF1 (nuclear respiratory factor 1) and EGR1 (early growth response 1) are central components of the transcription factor network regulating responses to LPS in non-pretreated cells (Fig. 7c, left panel).

In the context of the identified key transcription factors involved in the response to IFNγ + LPS, we observed that the downregulation of *Etv5* and *E2f8* occurred largely independently of STAT1 (Additional file 1: Fig. S10). In contrast, the expression of *Nfyb* and *Atf4* was elevated in the absence of STAT1 (Additional file 1: Fig. S10). The C-terminal TAD of STAT1 had a critical role in the collaborative upregulation of *Irf1* and *Irf8* in response to IFNγ and LPS, as well as *Stat1* in response to IFNγ (Additional file 1: Fig. S8). Consistent with our previous findings [26], we observed enhanced induction of *Irf7* by IFNγ in the absence of the STAT1 C-terminal TAD, which may partially explain the increased expression of a subset of ISGs (Additional file 1: Fig. S8).

Taken together, these data identify both novel and known transcriptional regulators and their target genes, providing mechanistic insights into the epigenetic and transcriptional crosstalk of IFNγ and LPS signalling.

Discussion

IFNγ is crucial for the immune response to viral and bacterial pathogens but is also associated with several autoinflammatory diseases and chronic mucocutaneous candidiasis [21, 55–57]. IFNγ not only induces its own transcriptional program but also synergizes with or antagonizes transcriptional responses to subsequent inflammatory stimuli [28, 29, 31, 58]. The underlying mechanisms have been extensively studied and include IFNγ-induced histone acetylation at promoter and enhancer elements [27].

Herein, we used primary macrophages from gene-targeted mice to investigate the role of the STAT1 C-terminal TAD in the genome-wide regulation of H3K27ac and H3K4me1 in response to IFNγ and analyse effects on subsequent transcriptional response to LPS. By focussing on STAT1 and its C-terminal TAD, we gained mechanistic insights into epigenetic and transcriptional regulation by IFNγ and its impact on responses to secondary inflammatory stimuli. Our approach enabled us to identify a gene-specific requirement for the STAT1 C-terminal TAD for H3K27 acetylation and deacetylation at promoter and enhancer elements and a particular importance of the STAT1 C-terminal TAD for the repressive activities of IFNγ on LPS-induced gene regulation.

One of the most notable findings of our study is that the STAT1 C-terminal TAD is not only essential for H3K27 acetylation at specific target genes but also has a critical role in H3K27 deacetylation in response to IFNγ. H3K27 deacetylation was found to be associated with the presence of motifs for AP-1 family members, rather than STAT1 itself. This suggest that the STAT1 C-terminal TAD regulates H3K27 deacetylation through indirect mechanisms, such as influencing the interplay between AP-1 and histone deacetylases (HDAC), modifying AP-1 activity or inducing co-repressors. Notably, IFNγ can both synergize with AP-1 family members to induce ISG expression during simultaneous exposure to IFNγ and stress, while also repressing AP-1-dependent gene expression in response to secondary TLR2 stimulation [59–61]. Surprisingly, cells only expressing STAT1α showed a profound increase in H3K27 deacetylation in response to IFNγ compared to *WT* cells at both promoter and enhancer elements, indicating that STAT1β has a crucial role in balancing STAT1α-mediated chromatin remodelling. Despite the profound alterations in H3K27 deacetylation in IFNγ-treated cells that only express STAT1α, transcriptional responses to subsequent LPS stimulation were comparable to those of *WT* cells. Further studies are needed to address if and how IFNγ-mediated H3K27 deacetylation impacts on subsequent responses to other stimuli.

Another important finding of our study is that IFNγ pretreatment represses the upregulation antiviral genes, including certain ISGs, in response to LPS stimulation, while simultaneously enhancing the induction of many genes annotated to the response to IFNβ. The suppression of antiviral gene induction by IFNγ can be seen as a mechanism to tailor macrophage responses to encountering bacterial pathogens. While IFNγ priming prioritizes front-line antibacterial effector functions (e.g.

phagocytosis, nitric oxide production and expression of GBP proteins), it avoids metabolically costly antiviral ISG expression upon LPS stimulation, improving efficiency and limiting collateral tissue damage.

The factors determining the differences in ISG regulation remain unclear. Both repressed and collaboratively induced ISGs were enriched in the highly similar, if not identical, consensus motifs recognized by ISGF3 and IRF family members [62, 63]. A similar divergent ISG expression pattern was also observed in human macrophages treated with IFNγ for several days before exposing them to IFNβ [29]. This study provided some evidence that specifically ISGF3-driven genes are suppressed by IFNγ pretreatment, albeit this needs confirmation. We found that IFNγ as well as LPS stimulation upregulate *Irf2*, which can competitively inhibit IRF1-mediated transcriptional activation [5]. It is therefore also possible that ISGs differ in their sensitivity to IRF2-mediated inhibition.

Importantly, IFNγ not only inhibited the expression of antiviral ISGs but also other genes annotated to the response to viruses or related functional categories in response to LPS. We demonstrate that the repression of gene induction by LPS depends on the presence of the STAT1 C-terminal TAD and involves inhibition of LPS-induced enhancer activation. Consistent with a previous report [31], we observed that IFNγ inhibits LPS-induced enhancer activation at the *Il10* gene, reinforcing the concept that IFNγ inhibits an LPS-induced negative feedback loop. Moreover, our finding that IFNγ blocks both enhancer activation and gene induction of *Irak3* extends this concept to another crucial negative regulator of TLR signalling cascade.

In contrast to the repressive activities of IFNγ on gene induction by LPS, the collaborative activities (additive or synergistic) were largely independent of the STAT1 C-terminal TAD. However, there were notable exceptions, such as *Ido1* and *Tgtp1*, whose synergistic activation by IFNγ and LPS was completely dependent on the presence of the C-terminal TAD of STAT1.

Mechanistically, we show that the enhancing effect of IFNγ pretreatment on LPS responses involves enhancer activation at a subset of LPS-induced genes. The effect on enhancer activation was largely independent of the STAT1 C-terminal TAD and, for example, observed at the *Il12p40* and *Tnfa* genes and at a subset of ISGs, such as the oncogene *Bcl9* and the checkpoint protein PD-L1-encoding gene *Cd274*. These findings support a previous study that showed IFNγ-induced enhancer activation at the *Il12p40* and *Tnfa* gene loci [31].

Another surprising finding of our study is the lack of evidence for a significant role of GAS elements in IFNγ-induced enhancer activation. Studies on selected ISGs demonstrated a gene-specific distribution of labour between STAT1 and IRF1 in the recruitment of histone modifying enzymes to promoter and enhancer regions [26, 64, 65]. Our findings suggest that at the genome-wide level, H3K27 acetylation is predominantly mediated by IRF1. Other factors that bind to ISRE/IRF elements, such as IFNγ-activated ISGF3 or non-canonical STAT1-containing complexes may also contribute, particular at late time points after stimulation [66]. Late IFNγ responses are marked by a switch from GAS to ISRE/IRF1 elements [67], raising the possibility that enhancer activation by STAT1 homodimers is not sustained throughout the treatment. Supporting the central role of IRF1 in IFNγ-induced chromatin remodelling, recent studies have shown that IRF1 is essential for opening inaccessible chromatin, which can subsequently be utilized by STAT1 homodimers to establish de novo enhancers in response to IFNγ [68].

Most of the past studies focused on gene induction by LPS and comparatively little is known about effects of IFNγ on genes that are repressed by LPS. We found that LPS-repressed genes that are affected by IFNγ pretreatment fall into two categories: collaboratively (synergistically or additively) repressed genes and genes whose repression is inhibited by IFNγ. We provide evidence for an involvement of E2F family members in the downregulation of gene expression by IFNγ and LPS. In line with the role of the E2F family in the regulation of the cell cycle [47], the collaboratively repressed genes mainly consisted of genes annotated to DNA replication and mitosis. Intriguingly, collaborative transcriptional downregulation by IFNγ and LPS was partially independent of STAT1 and did not involve effects of IFNγ on LPS-induced enhancer inactivation. Genes whose repression was inhibited by IFNγ mainly consisted of genes annotated to mitochondrial RNA metabolism and ribosome biogenesis. The mechanisms of how IFNγ blocks LPS-mediated downregulation remained unclear. However, we show that the inhibitory activity of IFNγ largely depends on the presence of STAT1 and its C-terminal TAD and, except for a small set of genes, does not involve enhancer inactivation.

Our transcription factor network analysis not only confirmed the central roles of STAT1, STAT2 and IRF9 but also underscores the importance of IRF1 and IRF8 in the transcriptional response to LPS in IFNγ-pretreated macrophages. Furthermore, the analysis identified MAZ, ETV5, NFYB, E2F8 and ATF4 as key regulators, with MAZ emerging as a pivotal factor governing the largest gene community and connecting to the IRF-STAT network. There is strong evidence that MAZ colocalizes with STAT1 on chromatin in response to IFNγ and positively regulates the expression of immune genes, including a subset of ISGs, but also negatively regulates gene expression in HAP1/K562 cells [69]. In line, we found

some ISGs, such as *Socs1* and *Cd274*, and activated as well as repressed genes in the list of MAZ target genes.

Our study has two limitations. First, our findings on the influence of the STAT1 C terminal TAD in IFNγ-induced priming on histone modification and transcription are based on comparing STAT1α (full length) and STAT1β (lacking the C-terminal TAD) without genome wide, time resolved DNA occupancy profiling. Prior studies indicate broadly similar binding of both isoforms to canonical GAS elements, with subtle differences in dimer-dimer formation and kinetics [12–14, 26]. Thus, while our data demonstrate a requirement for the STAT1 TAD, we cannot distinguish TAD-dependent cofactor recruitment from altered DNA binding (e.g., residence time or site selectivity) as the primary driver of the observed histone-modifying and transcriptional effects. Future isoform specific, time-resolved ChIP-seq or CUT&RUN coupled with interactome profiling will be needed to resolve underlying mechanisms. Second, our data establish a strong correlation between H3K27ac dynamics and gene expression, but do not demonstrate causality. Although, STAT1 isoform-specific perturbations link STAT1 domain architecture to H3K27ac dynamics and transcriptional outputs at defined loci, definitive tests of H3K27ac causality (e.g., targeted acetylation or deacetylation at specific enhancers) will be needed to establish whether H3K27ac is a driver, correlate, or consequence of transcriptional responses.

Beyond insights in STAT1 isoform-specific chromatin functions, our findings carry broader implications across immunology, host-pathogen evolution, and public health. The finding that IFNγ skews macrophage programs towards antibacterial activity, while repressing antiviral and anti-inflammatory pathways, support a model of adaptive trade-offs in which an IFNγ-primed antibacterial bias likely conferred fitness in bacterial-rich environments at the cost of transiently reduced antiviral readiness. Clinically, these data argue for temporally informed immunomodulation: distinguishing short-term priming from longer-lived innate memory will be critical for scheduling interventions that leverage IFNγ to enhance antibacterial defences when bacterial threat dominates yet avoid blunting antiviral responses in viral-prone settings or during co-infections. Epigenetically, our results provide a rationale to cautiously explore HDAC modulators to "tune" macrophage priming, with rigorous attention to dose, timing, and reversibility. Translationally, IFNγ-induced enhancer signatures and STAT1 isoform activity could serve as actionable biomarkers to guide patient stratification and therapeutic choice. Finally, population variation, including genetic or epigenetic factors that shift STAT1α/β ratios, may underlie inter-individual and ancestry-linked differences in infection outcomes, highlighting the need for precision strategies that account for host diversity and for societal efforts to align antimicrobial stewardship with immunomodulatory therapies.

Conclusions

This study reveals that IFNγ primes macrophages to restrain the induction of antiviral genes, including a subset of ISGs, while negative feedback regulators of TLR signalling. Additionally, IFNγ collaborates with LPS to block cell cycle genes and enhance the expression of a distinct set of ISGs. Our study also supports previous reports showing that IFNγ pretreatment promotes the expression of proinflammatory cytokines, while limiting LPS-induced IL-10. We find that STAT1 isoforms differentially mediate IFNγ-induced changes in H3K27 acetylation at promoters and enhancers, thereby shaping subsequent transcriptional responses to LPS. Integrating these results, our study predicts that a shift from the full-length STAT1α towards the C-terminally truncated STAT1β would dampen inflammatory gene expression while increasing antiviral activity in cells sequentially exposed to IFNγ and LPS. Our results help to better understand the interplay between transcription factor networks and the epigenome during infectious and inflammatory diseases.

Methods

Mice

C57BL/6N (Wild-type, *WT*), $Stat1^{-/-}$, $Stat1^{a/a}$ and $Stat1^{\beta/\beta}$ mice [22, 25] mice were bred at the University of Veterinary Medicine, Vienna. Mice were housed under specific-pathogen-free conditions according to Federation of European Laboratory Animal Science Associations (FELASA) guidelines at the animal facility of the Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna. All mice were on *C57BL/6* background. For the isolation of bone marrow, mice were euthanized with CO_2 to ensure a humane and gradual induction of unconsciousness. Mice were observed to verify unconsciousness before respiration ceased. This method was selected in accordance with regulations from the European Union (Directive 2010/63/EU on the protection of animals used for scientific purposes, Annex 4).

Bone marrow-derived macrophages (BMDM)

BMDM were differentiated and cultured from bone marrow of 8 to 12-week-old male mice. BMDM were differentiated for 7–9 days on Petri dishes (Greiner Bio-One) in DMEM (Sigma-Aldrich) supplemented with 10% FCS (Gibco/Thermo Fisher Scientific), 15% L929 cell-conditioned medium, 2 mM L-glutamine (Sigma-Aldrich), 100 U/ml penicillin, 100 µg/ml streptomycin, (Sigma-Aldrich) and 50 µM β-mercaptoethanol (Gibco/Thermo Fisher Scientific) at 37 °C and 5% CO_2 atmosphere.

BMDMs were stimulated with 100 U/mL IFNγ (Millipore, IF005) and 5 ng/mL LPS (Sigma, *Escherichia coli* 055: B5) for the times indicated.

$1{\cdot}10^6$ BMDMs were seeded on a 6-well plate (Falcon, 353224) and stimulated with IFNγ for 14 h. IFNγ was removed, cells were washed with PBS and LPS was added for the times indicated. Cells were placed on ice and washed with ice-cold PBS before harvesting for further analysis.

Reverse transcription-quantitative PCR (RT-qPCR)

Total RNA was isolated from cells or organs using TRIzol reagent (Invitrogen) according to the manufacturer's instructions and RT-qPCR was performed as described [25]. Following primers were used: *Ube2d2-fwd* 5'-AGG TCC TGT TGG AGA TGA TAT GTT-3', *Ube2d2-rev* 5'-TTG GGA AAT GAA TTG TCA AGA AA-3', *Ube2d2-FAM* 5'-CCA AAT GAC AGC CCC TAT CAG GGT GG-3'; *Tnf-fwd* 5'- CAA AAT TCG AGT GAC AAG CCT G-3', *Tnf-rev* 5'- GAG ATC CAT GCC GTT GGC-3', *Tnf-FAM* 5'- AGC CCA CGT CGT AGC AAA CCA CC; *Il12p40-fwd* 5'- GGA CGG TTC ACG TGC TCA T-3', *Il12p40-rev* 5'- TCC AGT GTG ACC TTC TCT GCA-3', *Il12p40-FAM* 5'- CCA TTC CAC ATG TCA CTG CCC GAG A-3'; I10-fwd 5'- TTT GAA TTC CCT GGG TGA GAA-3', *Il10-rev* 5'- GGA GAA ATC GAT GAC AGC GC, *Il10-FAM* 5'- CTG AAG ACC CTC AGG ATG CGG CTG A-3'.

Chromatin Immunoprecipitation (ChIP)

$5{\cdot}10^6$ BMDMs were seeded on 100 × 20 mm petri dish (Falcon, 353003) and stimulated with IFNγ for 14 h. IFNγ was removed and LPS was added for the times indicated. Cells were crosslinked with 1% formaldehyde (ThermoFisher Scientific, 28908) in PBS for 10 min (min) at room temperature (RT) on a shaker. Cells were quenched with 0.125 M glycine for 20 min at RT. Cells were harvested and washed twice in ice-cold PBS containing 1x protease inhibitor tablets (PI, Sigma-Aldrich, S8820-2TAB) and 1 mM PMSF (Sigma-Aldrich, SLBX4318). Cells were centrifuged for 5 min at 300 × g at 4 °C, pellets were snap-frozen in liquid nitrogen and stored at −80 °C overnight. Pellets were thawed on ice for 30 min and resuspended in 1 mL of sonication buffer (10 mM Tris pH 8.0, 0.25% SDS, 2mM EDTA) supplemented with 1 mM PMSF and 1x PI. Samples were sonicated in 15 mL polypropylene tubes (Falcon, 352099) suitable for the Bioruptor® Pico (Diagenode) for 20 min. Sonicated samples were centrifuged for 10 min at 14,000 × *g* at 4 °C and the supernatant was diluted in 1.5 mL equilibration buffer (10 mM Tris, 233 mM NaCl, 1.66% TritonX-100, 0.166% DOX, 1 mM EDTA, 1 mM PMSF, PI). 20% and 10% of total chromatin were used for each immunoprecipitation (IP) and input control, respectively. 1 mg of anti-H3K27ac (Diagenode, C15410196) or 2 mg of anti-H3K4me1 (Abcam, 8895) antibody was added to the sonicated chromatin aliquots. All samples were incubated on a rotator overnight at 4 °C.

Magnetic beads (ThermoFisher Scientific, 10004D) were washed twice in RIPA-LS buffer (10 mM Tris-HCL pH 8.0, 140 mM NaCl, 1mM EDTA pH 8.0, 0.1% SDS, 0.1% sodium deoxycholate, 1% triton X-100) containing 0.1% BSA. The beads were blocked overnight in RIPA-LS buffer containing 0.1% BSA at 4 °C. Input control samples were reversed crosslinked overnight at 65 °C. The next day 10 µl of the magnetic beads were added and samples were incubated 3 to 4 h at 4 °C (on a rotator). The beads were washed once with RIPA-LS buffer, RIPA-HS buffer (10 mM Tris-HCL pH 8.0, 500 mM NaCl, 1mM EDTA pH 8.0, 0.1% SDS, 0.1% sodium deoxycholate, 1% triton x-100), RIPA- LiCl buffer (10 mM Tris-HCL pH 8.0, 1mM EDTA pH 8.0, 0.5% sodium deoxycholate, 0.5% NP-40, 250 mM LiCl) and TE buffer (10 mM Tris-HCL pH 8, 1 mM EDTA). The beads were gently resuspended in a 25 mL tagmentation reaction mix. The tagmentation reaction mix contained 5x tagmentation buffer (50 mM Tris pH 8, 0.25% SDS, 2 mM EDTA), 19 mL nuclease-free water and 1x tagment DNA enzyme (Illumina, 15027865). The reaction mix was incubated for 10 min at 37 °C. The beads were washed once with RIPA-LS buffer and 10 mM Tris pH8 and then resuspended in 20 mM EDTA. Samples were heated for 30 min at 50 °C and 25 mL NEB Next High fidelity 2x master mix (NEB, M0480S) was pre-heated for 20 s at 98°. 10.5 mL 20 mM $MgCl_2$ was added to the master mix and the mixture was added to the samples. The samples were incubated for 5 min at 72 °C and 10 min at 95 °C and cooled on ice and 2x forward and barcoded reverse primers were added. Primers used for the ChIPseq analysis are listed in Additional file 6: Table S5. An enrichment PCR was performed with the following program: 98 °C for 30 s, 15 cycles (98 °C for 10 s, 63 °C for 30 s and 72 °C for 30 s) and 72 °C for 1 min. The supernatant was removed using Dynamag™–96 Side Magnet (ThermoFisher Scientific, 12331D) and stored at −80 °C. DNA from the input samples were eluted using Qiagen MinElute Kit (Qiagen, 28006). DNA was quantified using Qubit Fluorometer (ThermoFisher Scientific). To 2 ng of input DNA, 12 mL of the tagmentation reaction mix (1 mL of 5X tagmentation buffer, 1 mL of 1:10 diluted Tagment enzyme and nuclease-free water) was added. The tagmented input DNA was purified with a Qiagen MinElute kit. 2x forward, barcoded reverse primers and 20 mL NEBNext High fidelity 2X master mix were added to the eluted input DNA. An enrichment PCR was performed with the abovementioned program, except the cycle number was 12. The libraries of the samples and input controls were purified, and the size was selected by adding 2x AMPureXP beads (Beckman Coulter, A63880). The mixture was resuspended and incubated for 10 min

at RT. The supernatant was discarded, and the beads were washed twice with 80% EtOH for 5 s and air dried for 5 min on the magnet. The beads were removed from the magnet to elute the DNA, and 50 mL of water was added for 10 min at RT. The beads were placed back on the magnet for 5 min, and the supernatant was removed into a new tube. DNA was measured on the Qubit Fluorometer. For quality check, the fragment size of the DNA was analyzed on Agilent High Sensitivity D1000 TapeStation. 4 nM of samples were pooled according to barcode and DNA fragment size. Samples were sequenced at the CeMM biomedical sequencing facility in Vienna, Austria.

ChIP-seq analysis

Preprocessing and alignment

ChIP-seq reads were processed using fastp v0.23.4 [70], where adapter and low-quality bases were trimmed. Trimmed reads were then aligned against the NCBI RefSeq GRCm38.p6 mouse reference genome using bowtie2 v2.3.5.1 [71]. Mapped reads were then filtered to remove reads with mapping quality Q < 30 using samtools v1.16 [72]. Normalized ChIP seq signal enrichment was generated using deepTools [73] by calculating the log2 ratio of the RPGC normalized target IP over input IgG.

Peak calling and consensus peak derivation

Broad peaks per sample were called using MACS3 [74] setting the slocal to 500, llocal to 5000 and the q-value threshold to 0.05. Peaks were filtered to exclude regions that overlap with ENCODE blacklisted regions [75]. For generating correlation heatmaps, per sample binned (10 kb bins) coverage was calculated using the "multiBamSummary" command from the deepTools v3.5.2 suite and the pairwise Pearson correlation was calculated. Samples were clustered using the "hclust" R package using the 1-r as distance metric and setting the linkage to "Ward.D2". Jaccard similarity was calculated using "bedtools jaccard" from the bedtools v2.31.0 suite. Samples were clustered using the "hclust" R package using the 1-jaccard as distance metric and setting the linkage to "single".

To generate a H3K27ac consensus peak set out of all peak sets all overlapping and bookend peaks across all samples were merged into contigs using bedops [76] and the number of overlapping peaks per contig is recorded. Contigs that consist of a single peak were used as-is. For contigs consisting of 2 peaks the consensus region is defined as the intersection of peaks that overlap by ≥ 50%. For contigs that consist of 3 peaks, we identify all the input peaks that overlap these contigs and merge them into a single consensus peak. For contigs that consist of > 3 peaks, the per base number of overlaps is calculated across each contig. Per base overlaps are then smoothed by applying a gaussian kernel with a variable smoothing window empirically calculated. Local minima and maxima of the per base smoothed overlaps are calculated over a rolling window, proportional to the gaussian kernel window. Peaks within a contig are defined by their flanking valleys. Finally, the consensus region within a peak is defined as the full width at half maximum (FWHM). Consensus H3K27ac peaks were annotated and quantified using annotatePeaks.pl from HOMER [77].

To quantify IFNγ induced changes genome-wide, for each target (consensus H3K27ac or H3K4me1) the normalized signal enrichment of IP over IgG input was calculated using the "bigWigCompare" tool from the deepTools v3.5.2 suite. Then the genome-wide, binned (500 bp bins) log2 ratio of the signal enrichment between IFNγ treated and untreated samples was calculated using the "bigWigCompare" from the deepTools v3.5.2 suite.

Motif enrichment

De novo and known motif analysis was performed using the "findMotifsGenome.pl" tool from the HOMER v4.11 suite. Motif enrichment between groups of consensus peaks was performed using a custom implementation as previously described [78]. Briefly, non-redundant transcription factor motif archetypes derived from GRCm38 at p < 1e-04 [79] were mapped to peaks using bedops [76] and the counts of each motif archetype per group was calculated. Over- or under-representation of every motif archetype for each group was tested using a hypergeometric enrichment using the frequency of the motif in the rest of the groups as the expected probability. Hypergeometric test p-values were then corrected for multiple testing using FDR adjustment.

Differential peak activity analysis

Differential H3K27ac signal analysis between groups of samples was performed using DESeq2 [66]. H3K27ac raw signal over peaks was quantified using HOMER [77] and the count matrix was supplied to DESeq2. For pairwise testing the Wald test was applied while identification of peaks that display differential H3K27ac enrichment across multiple conditions the likelihood ratio test (LRT) against a null model was used. Differentially active peaks were called at 0.05 Benjamini-Hochberg adjusted p-value. In the pairwise Wald test comparisons, peaks with significant differential H3K27ac levels were called at absolute log2 fold change > 1 and Benjamini-Hochberg adjusted p-value ≤ 0.05.

Enhancer class assignment

Distal H3K27ac consensus peaks (> 1000 bp from nearest TSS) were classified into activated and inactivated enhancer elements, independently for each genotype and treatment combination, based on H3K27ac and H3K4me1 levels. Specifically, we defined activated

enhancers for each of the LPS, IFNγ, and IFNγ + LPS conditions the H3K27ac consensus peaks which have < 30 normalized H3K27ac counts and ≥ 10 normalized H3K4me1 counts in untreated state and upon treatment they maintain ≥ 10 normalized H3K4me1 counts while H3K27ac levels are ≥ 30 normalized counts. Similarly, inactivated enhancers are defined as the elements that in the untreated condition are positive for H3K27ac and H3K4me1 (≥ 30 and ≥ 10 normalized counts, respectively) and but lose H3K27ac (< 30 normalized counts) upon treatment while H3K4me1 remains ≥ 10 normalized counts. Elements with shared classes across genotypes were identified and archetype motif enrichment was performed as described above.

RNA-seq analysis

Transcriptome profiling using Smart-seq2

Total RNA was isolated using AllPrep DNA/RNA Mini Kit (Qiagen, 80204) according to the manufacturer's instructions. 500 pg of RNA was used as input. Reverse transcription and PCR were performed as described [80]. Library preparation was conducted on 1 ng of cDNA using the Nextera XT DNA Sample Preparation Kit (Illumina) followed by SPRI (Beckman Coulter) size selection. Sequencing was performed by the Bio-medical Sequencing Facility at CeMM using the Illumina HiSeq 3000/4000 platform and the 50 bp single end configuration.

Preprocessing and alignment of the RNA-seq data

RNA-seq data were processed and quality-controlled using established bioinformatics software. Raw reads were trimmed using trimmomatic (v.0.32) [81] and aligned to the mouse reference genome (mm10) using STAR (v.2.7.1) [82]. Gene expression was quantified by counting uniquely aligned reads in exons using the function summarizeOverlaps from the GenomicAlignments package (v.1.6.3) in R (v.3.2.3). Gene annotations were based on the Ensembl GENCODE Basic set (genome build GRCm38 release 93) [83].

Differential gene expression analysis

The gene count matrix was initially filtered to exclude genes where the mean counts across all samples was less than 5 raw counts. To identify any source of variation, the top variable genes (genes that account for the 50% of total variation observed) were used and a principal component analysis was performed. Identification of differentially expressed genes across conditions was performed using DESeq2 by applying LRT against a null model. Significantly changing genes across groups were called at ≤ 0.01 Benjamini-Hochberg adjusted p-value. Gene Ontology over-representation analysis is performed using the R package clusterProfiler [84] testing for enrichment for each of the three GO terms (Biological Processes-BP, Molecular Function-MF, and Cellular Compartment-CC). All significantly changing genes (LRT Benjamini-Hochberg adjusted p-value ≤ 0.01) genes were used as background.

Gene regulatory network analysis

Gene regulatory network analysis was performed using the Bioconductor package GRaNIE (version 1.12.0) [54], together with our RNA-seq read counts, acetylated peak locations and read counts, and motif scans for the top 150 most variable transcription factors (according to variance across RNA-seq data from *WT* and *Stat1*$^{-/-}$ cells) available in HOCOMOCO (version 12) [85]. GRaNIE parameters were set to Spearman as the TF-peak, peak-gene and TF-gene correlation method, and maximal peak-gene distance was set to 250 kb. Graphs have been generated using the igraph R package [86], R package version 2.1.4, https://CRAN.R-project.org/package=igraph.]. Annotations of the putative target genes as ISG and transcriptional regulators were based on AnimalTFDB version 4.0 [87] and the ISG list provided by Karjalainen et al. [88], respectively.

Statistical analyses

Statistical analyses were performed in R 4.2.2 and in GraphPad Prism version 10. P-values and correction tests are reported throughout along with the statistical test performed and the sample sizes, where applicable.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12864-026-12601-5.

Supplementary Material 1.

Supplementary Material 2.

Supplementary Material 3.

Supplementary Material 4.

Supplementary Material 5.

Supplementary Material 6.

Acknowledgements

We are grateful to Maria Liivrand (Genevia Technologies) for the original data analysis, Andrea Pölzl for her help with the RNA-seq and ChIP-seq experiments and Therese Lederer for the illustrations of the experimental workflow.

Authors' contributions

MJA, KM and BS designed the study with input from MM and TD. MJA conducted the experiments with help from KM and LA. NF performed the preprocessing of the RNA-seq and ChIP-seq data. MF provided technical input for the overall study. GG designed and performed the bioinformatics analysis. DM helped with data analysis and visualization and performed the transcription factor network analysis. CV helped with statistical analysis. MJA wrote the first draft of the manuscript. TD, MM and FH provided critical input. BS prepared the figures and wrote the manuscript together with GG and input from all co-authors.

Funding
This work was supported by the Austrian Science Fund (FWF) SFB-F6101 and SFB-F6106 to MM and SFB-F6103 to TD. The work was furthermore supported in part by the FWF-funded project P34286-B to BS.

Data availability
The datasets generated during the current study have been deposited in NCBI's Gene Expression Omnibus [89, 90] and are accessible through GEO series accession numbers GSE309564 (RNA-seq; https://identifiers.org/geo: GSE309564) and GSE309503 (ChIP-seq; https://identifiers.org/geo: GSE309503).

Declarations

Ethics approval and consent to participate
Mice were kept in specific-pathogen-free conditions according to Federation of European Laboratory Animal Science Associations (FELASA) guidelines, with standard chow diet and water ad libitum. The room temperature for the mice was 20 °C to 22 °C, with relative humidity of 55 ± 10% and 12-h light/dark cycles (light period from 6:00 to 18:00). No in vivo experimental perturbations, such as infection or other immune stimuli, were used in this study. Mice were bred as approved by the Ethics and Animal Welfare Committee of the University of Veterinary Medicine Vienna in accordance with the university's guidelines for Good Scientific Practice and authorized by the Austrian Federal Ministry of Education, Science and Research (BMWFW-68.205/0068-WF/V/3b/2015, BMBWF_GZ:2020 – 0.200.397) in accordance with current legislation.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Received: 14 October 2025 / Accepted: 28 January 2026
Published online: 05 February 2026

References

1. Ross EA, Devitt A, Johnson JR. Macrophages: The Good, the Bad, and the Gluttony. Front Immunol. 2021;12:708186.
2. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163–89.
3. Decker T, Kovarik P, Meinke A. GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res. 1997;17(3):121–34.
4. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651–62.
5. Babadei O, Strobl B, Müller M, Decker T. Transcriptional control of interferon-stimulated genes. J Biol Chem. 2024;300(10):107771.
6. Morrow AN, Schmeisser H, Tsuno T, Zoon KC. A novel role for IFN-stimulated gene factor 3II in IFN-γ signaling and induction of antiviral activity in human cells. J Immunol. 2011;186(3):1685–93.
7. Bluyssen AR, Durbin JE, Levy DE. ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. Cytokine Growth Factor Rev. 1996;7(1):11–7.
8. Majumder S, Zhou LZ, Chaturvedi P, Babcock G, Aras S, Ransohoff RM. Regulation of human IP-10 gene expression in Astrocytoma cells by inflammatory cytokines. J Neurosci Res. 1998;54(2):169–80.
9. Rauch I, Rosebrock F, Hainzl E, Heider S, Majoros A, Wienerroither S, Strobl B, Stockinger S, Kenner L, Müller M, Decker T. Noncanonical effects of IRF9 in intestinal inflammation: more than type I and type III interferons. Mol Cell Biol. 2015;35(13):2332–43.
10. Udupa A, Kotha SR, Staller MV. Commonly asked questions about transcriptional activation domains. Curr Opin Struct Biol. 2024;84:102732.
11. Müller M, Laxton C, Briscoe J, Schindler C, Improta T, Darnell JE Jr., et al. Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-alpha and -gamma signal transduction pathways. EMBO J. 1993;12(11):4221–8.
12. Shuai K, Stark GR, Kerr IM, Darnell JE Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science. 1993;261(5129):1744–6.
13. Zakharova N, Lymar ES, Yang E, Malik S, Zhang JJ, Roeder RG, et al. Distinct transcriptional activation functions of STAT1alpha and STAT1beta on DNA and chromatin templates. J Biol Chem. 2003;278(44):43067–73.
14. Vinkemeier U, Cohen SL, Moarefi I, Chait BT, Kuriyan J, Darnell JE Jr. DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO J. 1996;15(20):5616–26.
15. Paulson M, Pisharody S, Pan L, Guadagno S, Mui AL, Levy DE. Stat protein transactivation domains recruit p300/CBP through widely divergent sequences. J Biol Chem. 1999;274(36):25343–9.
16. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D'Andrea A, Livingston DM. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature. 1996;383(6598):344–7.
17. Qureshi SA, Leung S, Kerr IM, Stark GR, Darnell JE Jr. Function of Stat2 protein in transcriptional activation by alpha interferon. Mol Cell Biol. 1996;16(1):288–93.
18. DaFonseca CJ, Shu F, Zhang JJ. Identification of two residues in MCM5 critical for the assembly of MCM complexes and Stat1-mediated transcription activation in response to IFN-gamma. Proc Natl Acad Sci U S A. 2001;98(6):3034–9.
19. Ouchi T, Lee SW, Ouchi M, Aaronson SA, Horvath CM. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes. Proc Natl Acad Sci U S A. 2000;97(10):5208–13.
20. Zhang JJ, Zhao Y, Chait BT, Lathem WW, Ritzi M, Knippers R, et al. Ser727-dependent recruitment of MCM5 by Stat1alpha in IFN-gamma-induced transcriptional activation. EMBO J. 1998;17(23):6963–71.
21. Boisson-Dupuis S, Kong XF, Okada S, Cypowyj S, Puel A, Abel L, Casanova JL. Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr Opin Immunol. 2012;24(4):364–78.
22. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 1996;84(3):443–50.
23. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 1996;84(3):431–42.
24. Nishibori T, Tanabe Y, Su L, David M. Impaired development of CD4 + CD25+ regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease. J Exp Med. 2004;199(1):25–34.
25. Semper C, Leitner NR, Lassnig C, Parrini M, Mahlakõiv T, Rammerstorfer M, Lorenz K, Rigler D, Müller S, Kolbe T, Vogl C, Rülicke T, Staeheli P, Decker T, Müller M, Strobl B. STAT1β is not dominant negative and is capable of contributing to gamma interferon-dependent innate immunity. Mol Cell Biol. 2014;34(12):2235–48.
26. Parrini M, Meissl K, Ola MJ, Lederer T, Puga A, Wienerroither S, et al. The C-terminal transactivation domain of STAT1 has a gene-specific role in transactivation and cofactor recruitment. Front Immunol. 2018;9:2879.
27. Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18(9):545–58.
28. Akhter N, Kochumon S, Hasan A, Wilson A, Nizam R, Al Madhoun A, et al. IFN-γ and LPS induce synergistic expression of CCL2 in monocytic cells via H3K27 acetylation. J Inflamm Res. 2022;15:4291–302.
29. Cheng Q, Behzadi F, Sen S, Ohta S, Spreafico R, Teles R, et al. Sequential conditioning-stimulation reveals distinct gene- and stimulus-specific effects of type I and II IFN on human macrophage functions. Sci Rep. 2019;9(1):5288.
30. Divangahi M, Aaby P, Khader SA, Barreiro LB, Bekkering S, Chavakis T, et al. Trained immunity, tolerance, priming and differentiation: distinct immunological processes. Nat Immunol. 2021;22(1):2–6.
31. Qiao Y, Giannopoulou EG, Chan CH, Park SH, Gong S, Chen J, Hu X, Elemento O, Ivashkiv LB. Synergistic activation of inflammatory cytokine genes by interferon-γ-induced chromatin remodeling and toll-like receptor signaling. Immunity. 2013;39(3):454–69.
32. Kang K, Bachu M, Park SH, Kang K, Bae S, Park-Min KH, et al. IFN-γ selectively suppresses a subset of TLR4-activated genes and enhancers to potentiate macrophage activation. Nat Commun. 2019;10(1):3320.
33. Calo E, Wysocka J. Modification of enhancer chromatin: what, how, and why? Mol Cell. 2013;49(5):825–37.

34. Real R, Varga JM. The probabilistic basis of jaccard's index of similarity. Syst Biol. 1996;45(3):380–5.
35. Ray D, Bosselut R, Ghysdael J, Mattei MG, Tavitian A, Moreau-Gachelin F. Characterization of Spi-B, a transcription factor related to the putative oncoprotein Spi-1/PU.1. Mol Cell Biol. 1992;12(10):4297–304.
36. Solomon LA, Li SK, Piskorz J, Xu LS, DeKoter RP. Genome-wide comparison of PU.1 and Spi-B binding sites in a mouse B lymphoma cell line. BMC Genomics. 2015;16(1):76.
37. Medzhitov R, Horng T. Transcriptional control of the inflammatory response. Nat Rev Immunol. 2009;9(10):692–703.
38. Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006;13(5):816–25.
39. Ostuni R, Piccolo V, Barozzi I, Polletti S, Termanini A, Bonifacio S, Curina A, Prosperini E, Ghisletti S, Natoli G. Latent enhancers activated by stimulation in differentiated cells. Cell. 2013;152(1–2):157–71.
40. Platanitis E, Demiroz D, Schneller A, Fischer K, Capelle C, Hartl M, et al. A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription. Nat Commun. 2019;10(1):2921.
41. Sekimata M, Homma Y. Sequence-specific transcriptional repression by an MBD2-interacting zinc finger protein MIZF. Nucleic Acids Res. 2004;32(2):590–7.
42. Sekimata M, Takahashi A, Murakami-Sekimata A, Homma Y. Involvement of a novel zinc finger protein, MIZF, in transcriptional repression by interacting with a methyl-CpG-binding protein, MBD2. J Biol Chem. 2001;276(46):42632–8.
43. Heintzman ND, Ren B. Finding distal regulatory elements in the human genome. Curr Opin Genet Dev. 2009;19(6):541–9.
44. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007;39(3):311–8.
45. Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ, Hanna J, Lodato MA, Frampton GM, Sharp PA, Boyer LA, Young RA, Jaenisch R. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A. 2010;107(50):21931–6.
46. Meissl K, Macho-Maschler S, Müller M, Strobl B. The good and the bad faces of STAT1 in solid tumours. Cytokine. 2017;89:12–20.
47. Attwooll C, Lazzerini Denchi E, Helin K. The E2F family: specific functions and overlapping interests. EMBO J. 2004;23(24):4709–16.
48. Rothschild DE, McDaniel DK, Ringel-Scaia VM, Allen IC. Modulating inflammation through the negative regulation of NF-κB signaling. J Leukoc Biol. 2018. https://doi.org/10.1002/jlb.3mir0817-346rrr.
49. Warszawska JM, Gawish R, Sharif O, Sigel S, Doninger B, Lakovits K, Mesteri I, Nairz M, Boon L, Spiel A, Fuhrmann V, Strobl B, Müller M, Schenk P, Weiss G, Knapp S. Lipocalin 2 deactivates macrophages and worsens Pneumococcal pneumonia outcomes. J Clin Invest. 2013;123(8):3363–72.
50. Hayes MP, Freeman SL, Donnelly RP. IFN-gamma priming of monocytes enhances LPS-induced TNF production by augmenting both transcription and mRNA stability. Cytokine. 1995;7(5):427–35.
51. Takeshita S, Nakatani K, Takata Y, Kawase H, Sekine I, Yoshioka S. Interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) enhance lipopolysaccharide binding to neutrophils via CD14. Inflamm Res. 1998;47(3):101–3.
52. Wu C, Xue Y, Wang P, Lin L, Liu Q, Li N, Xu J, Cao X. IFN-γ primes macrophage activation by increasing phosphatase and tensin homolog via downregulation of miR-3473b. J Immunol. 2014;193(6):3036–44.
53. Lara-Astiaso D, Weiner A, Lorenzo-Vivas E, Zaretsky I, Jaitin DA, David E, et al. Chromatin state dynamics during blood formation. Science. 2014;345(6199):943–9.
54. Kamal A, Arnold C, Claringbould A, Moussa R, Servaas NH, Kholmatov M, et al. GRaNIE and GRaNPA: inference and evaluation of enhancer-mediated gene regulatory networks. Mol Syst Biol. 2023;19(6):e11627.
55. Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Semin Immunol. 2014;26(6):454–70.
56. Casanova JL, MacMicking JD, Nathan CF. Interferon-γ and infectious diseases: lessons and prospects. Science. 2024;384(6693):eadl2016.
57. Pollard KM, Cauvi DM, Toomey CB, Morris KV, Kono DH. Interferon-γ and systemic autoimmunity. Discov Med. 2013;16(87):123–31.
58. Leopold Wager CM, Hole CR, Campuzano A, Castro-Lopez N, Cai H, Van Caballero MC, Wozniak KL, Wang Y, Wormley FL. Jr. IFN-γ immune priming of macrophages in vivo induces prolonged STAT1 binding and protection against Cryptococcus neoformans. PLoS Pathog. 2018;14(10):e1007358.
59. Boccuni L, Podgorschek E, Schmiedeberg M, Platanitis E, Traxler P, Fischer P, Schirripa A, Novoszel P, Nebreda AR, Arthur JSC, Fortelny N, Farlik M, Sexl V, Bock C, Sibilia M, Kovarik P, Müller M, Decker T. Stress signaling boosts interferon-induced gene transcription in macrophages. Sci Signal. 2022;15(764):eabq5389.
60. Ho HH, Antoniv TT, Ji JD, Ivashkiv LB. Lipopolysaccharide-induced expression of matrix metalloproteinases in human monocytes is suppressed by IFN-gamma via superinduction of ATF-3 and suppression of AP-1. J Immunol. 2008;181(7):5089–97.
61. Hu X, Chen J, Wang L, Ivashkiv LB. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol. 2007;82(2):237–43.
62. Negishi H, Taniguchi T, Yanai H. The interferon (IFN) class of cytokines and the IFN regulatory factor (IRF) transcription factor family. Cold Spring Harb Perspect Biol. 2018;10(11):a028423.
63. Schmid S, Mordstein M, Kochs G, García-Sastre A, Tenoever BR. Transcription factor redundancy ensures induction of the antiviral state. J Biol Chem. 2010;285(53):42013–22.
64. Ramsauer K, Farlik M, Zupkovitz G, Seiser C, Kröger A, Hauser H, Decker T. Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-gamma-inducible gbp2 gene. Proc Natl Acad Sci U S A. 2007;104(8):2849–54.
65. Wienerroither S, Shukla P, Farlik M, Majoros A, Stych B, Vogl C, Cheon H, Stark GR, Strobl B, Müller M, Decker T. Cooperative transcriptional activation of antimicrobial genes by STAT and NF-κB pathways by concerted recruitment of the mediator complex. Cell Rep. 2015;12(2):300–12.
66. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
67. Geetha RSJ, Fischer A, Babadei K, Smesnik O, Vogt G, Platanitis A, et al. Dynamic control of gene expression by ISGF3 and IRF1 during IFNβ and IFNγ signaling. EMBO J. 2024;43(11):2233–63.
68. Chavez C, Lin K, Malveaux A, Gorin A, Brizuela S, Cheng QJ, et al. IRF1 cooperates with ISGF3 or GAF to form innate immune de novo enhancers in macrophages. Sci Signal. 2025;18(868):eado8860.
69. Xiao T, Li X, Felsenfeld G. The Myc-associated zinc finger protein epigenetically controls expression of interferon-γ-stimulated genes by recruiting STAT1 to chromatin. Proc Natl Acad Sci U S A. 2024;121(17):e2320938121.
70. Chen S, Zhou Y, Chen Y, Gu J. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884–90.
71. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357–9.
72. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, Whitwham A, Keane T, McCarthy SA, Davies RM, Li H. Twelve years of samtools and BCFtools. Gigascience. 2021;10(2):giab008.
73. Ramírez F, Ryan DP, Grüning B, Bhardwaj V, Kilpert F, Richter AS, et al. Deeptools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 2016;44(W1):W160-165.
74. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-seq (MACS). Genome Biol. 2008;9(9):R137.
75. Amemiya HM, Kundaje A, Boyle AP. The ENCODE blacklist: identification of problematic regions of the genome. Sci Rep. 2019;9(1):9354.
76. Neph S, Kuehn MS, Reynolds AP, Haugen E, Thurman RE, Johnson AK, Rynes E, Maurano MT, Vierstra J, Thomas S, Sandstrom R, Humbert R, Stamatoyannopoulos JA. BEDOPS: high-performance genomic feature operations. Bioinformatics. 2012;28(14):1919–20.
77. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38(4):576–89.
78. Georgolopoulos G, Psatha N, Iwata M, Nishida A, Som T, Yiangou M, et al. Discrete regulatory modules instruct hematopoietic lineage commitment and differentiation. Nat Commun. 2021;12(1):6790.
79. Vierstra J, Lazar J, Sandstrom R, Halow J, Lee K, Bates D, Diegel M, Dunn D, Neri F, Haugen E, Rynes E, Reynolds A, Nelson J, Johnson A, Frerker M, Buckley M, Kaul R, Meuleman W, Stamatoyannopoulos JA. Global reference mapping of human transcription factor footprints. Nature. 2020;583(7818):729–36.
80. Picelli S, Faridani OR, Björklund AK, Winberg G, Sagasser S, Sandberg R. Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc. 2014;9(1):171–81.
81. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics. 2014;30(15):2114–20.

82. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.
83. Frankish A, Diekhans M, Ferreira AM, Johnson R, Jungreis I, Loveland J, Mudge JM, Sisu C, Wright J, Armstrong J, Barnes I, Berry A, Bignell A, Carbonell Sala S, Chrast J, Cunningham F, Di Domenico T, Donaldson S, Fiddes IT, García Girón C, Gonzalez JM, Grego T, Hardy M, Hourlier T, Hunt T, Izuogu OG, Lagarde J, Martin FJ, Martínez L, Mohanan S, Muir P, Navarro FCP, Parker A, Pei B, Pozo F, Ruffier M, Schmitt BM, Stapleton E, Suner MM, Sycheva I, Uszczynska-Ratajczak B, Xu J, Yates A, Zerbino D, Zhang Y, Aken B, Choudhary JS, Gerstein M, Guigó R, Hubbard TJP, Kellis M, Paten B, Reymond A, Tress ML, Flicek P. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 2019;47(D1):D766–73.
84. Yu G, Wang LG, Han Y, He QY. Clusterprofiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284–7.
85. Kulakovskiy IV, Vorontsov IE, Yevshin IS, Sharipov RN, Fedorova AD, Rumynskiy EI, Medvedeva YA, Magana-Mora A, Bajic VB, Papatsenko DA, Kolpakov FA, Makeev VJ. HOCOMOCO: towards a complete collection of transcription factor binding models for human and mouse via large-scale ChIP-Seq analysis. Nucleic Acids Res. 2018;46(D1):D252–9.
86. Csárdi G, Nepusz T, Traag V, Horvát S, Zanini F, Noom D, Müller K. igraph: Network analysis and visualization in R. 2025, https://doi.org/10.5281/zenodo.7682609
87. Shen WK, Chen SY, Gan ZQ, Zhang YZ, Yue T, Chen MM, Xue Y, Hu H, Guo AY. AnimalTFDB 4.0: a comprehensive animal transcription factor database updated with variation and expression annotations. Nucleic Acids Res. 2023;51(D1):D39–45.
88. Karjalainen A, Witalisz-Siepracka A, Prchal-Murphy M, Martin D, Sternberg F, Krunic M, Dolezal M, Fortelny N, Farlik M, Macho-Maschler S, Lassnig C, Meissl K, Amenitsch L, Lederer T, Pohl E, Gotthardt D, Bock C, Decker T, Strobl B, Müller M. Cell-type-specific requirement for TYK2 in murine immune cells under steady state and challenged conditions. Cell Mol Life Sci. 2025;82(1):98.
89. Clough E, Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Lee H, Zhang N, Serova N, Wagner L, Zalunin V, Kochergin A, Soboleva A. NCBI GEO: archive for gene expression and epigenomics data sets: 23-year update. Nucleic Acids Res. 2024;52(D1):D138–44.
90. Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–10.

Publisher's Note